PRMT5 levels positively correlate with malignancy and negatively correlate with glioma patients’ survival27,28, therefore justifying the efforts to identify specific pharmacological inhibitors as potential therapeutic targets27,29–33. Here, PRMT5 is linked to central nervous system cancer.